NRIX

$15.0941.56%-10.73

Nurix Therapeutics Inc (NRIX)

Date: O: H: L: C: Vol:

Precedente Chiudi:

$25.82

Aprire:

$17.16

Volume 24 ore:

9,058,894

Volume relativo:

3.62

Capitalizzazione di mercato:

$1.65B

Reddito:

$71.78M

Utile/perdita netta:

-$295.28M

Rapporto P/E:

EPS:

-$3.16

Flusso di cassa netto:

-$271.85M

1W Prestazione:

-44.65%

1M Prestazione:

-34.36%

6M Prestazione:

-10.87%

1Y Prestazione:

+23.08%

Intervallo 1D:

$14.78$17.28

Intervallo di 1 settimana:

$25.53$27.99

Portata 52W:

$11.67$28.23

Profilo aziendale di Nurix Therapeutics Inc (NRIX)

Nome

Nurix Therapeutics Inc

Settore

Healthcare

Industria

Biotechnology

Telefono

(415) 660-5320

Indirizzo

1600 SIERRA POINT PKWY, BRISBANE, USA

Dipendente

317

Prossima data di guadagno

null

Ultimi documenti SEC

SEC

Discussioni di NRIX su X

Cap. di mercato

Reddito

Reddito netto

Flusso di cassa

EPS

Nurix Therapeutics Inc Azioni (NRIX) Upgrade e downgrade

Data	Azione	Analista	Modifica della valutazione
2026-06-29	Resumed	Oppenheimer	Outperform
2026-01-08	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2025-11-24	Resumed	Truist	Buy
2025-10-21	Iniziato	Mizuho	Outperform
2025-03-17	Iniziato	Leerink Partners	Market Perform
2024-12-10	Iniziato	BTIG Research	Buy
2024-12-06	Iniziato	BMO Capital Markets	Outperform
2024-10-24	Iniziato	UBS	Buy
2024-10-11	Iniziato	Jefferies	Buy
2024-09-06	Resumed	Robert W. Baird	Outperform
2024-07-31	Iniziato	Truist	Buy
2023-06-26	Resumed	Oppenheimer	Outperform
2023-03-09	Iniziato	Barclays	Overweight
2023-02-28	Iniziato	Oppenheimer	Outperform
2022-10-11	Iniziato	Morgan Stanley	Equal-Weight
2022-05-31	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2022-02-10	Iniziato	Wells Fargo	Equal Weight
2021-12-29	Iniziato	H.C. Wainwright	Buy
2021-10-14	Iniziato	SVB Leerink	Outperform
2021-06-04	Resumed	Robert W. Baird	Outperform
2021-04-30	Resumed	Piper Sandler	Overweight
2021-04-30	Iniziato	RBC Capital Mkts	Outperform
2021-04-14	Iniziato	Berenberg	Buy
2020-11-19	Iniziato	Robert W. Baird	Outperform
2020-08-18	Iniziato	JP Morgan	Overweight
2020-08-18	Iniziato	Needham	Buy
2020-08-18	Iniziato	Piper Sandler	Overweight
2020-08-18	Iniziato	Stifel	Buy

Nurix Therapeutics Inc Azioni (NRIX) Dati Finanziari

Periodo	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Data di fine periodo	2025-11-30	2024-11-30	2023-11-30	2022-11-30	2021-11-30
Revenue USD (M)	83.98	54.55	76.99	38.63	29.75
Research and development USD (M)	316.90	221.63	189.15	184.50	116.43
Operating expenses USD (M)	369.65	267.58	232.05	222.49	147.64
Operating income USD (M)	-285.67	-213.03	-155.06	-183.87	-117.89
Income before tax USD (M)	-263.70	-193.30	-143.95	-180.36	-117.06
Income tax expense USD (M)	0.76	0.27	-	0.00	0.13
Net income USD (M)	-264.46	-193.57	-143.95	-180.36	-117.19
Basic EPS USD/shares	-3.05	-2.88	-2.65	-3.71	-
Diluted EPS USD/shares	-3.05	-2.88	-2.65	-3.71	-
Basic weighted shares shares (M)	86.67	67.12	54.34	48.61	-
Diluted weighted shares shares (M)	86.67	67.12	54.34	48.61	-

Nurix Therapeutics Inc Azioni (NRIX) insider trading

CHRISTINE RINGNov 03 '26
Officer
Transazione
Proposed Sale
Costo
$25.70
#Azioni
6,113
Valore ($)
157,104
#Azioni Totale
0
CHRISTINE RINGNov 02 '26
Officer
Transazione
Proposed Sale
Costo
$26.80
#Azioni
10,602
Valore ($)
284,134
#Azioni Totale
0
Hansen GwennNov 02 '26
Chief Scientific Officer
Transazione
Sale
Costo
$26.80
#Azioni
1,452
Valore ($)
38,914
#Azioni Totale
123,452
Hansen GwennNov 02 '26
Chief Scientific Officer
Transazione
Option Exercise
Costo
$1.86
#Azioni
1,452
Valore ($)
2,701
#Azioni Totale
124,904
Hansen GwennOct 30 '26
Chief Scientific Officer
Transazione
Sale
Costo
$26.28
#Azioni
3,957
Valore ($)
103,986
#Azioni Totale
123,452
van Houte HansOct 30 '26
Chief Financial Officer
Transazione
Sale
Costo
$26.28
#Azioni
2,834
Valore ($)
74,475
#Azioni Totale
47,514
Ring ChristineOct 30 '26
Chief Legal Officer
Transazione
Option Exercise
Costo
$0.00
#Azioni
10,182
Valore ($)
0
#Azioni Totale
19,292
Ring ChristineOct 30 '26
Chief Legal Officer
Transazione
Sale
Costo
$26.28
#Azioni
3,957
Valore ($)
103,986
#Azioni Totale
15,335
van Houte HansOct 30 '26
Chief Financial Officer
Transazione
Option Exercise
Costo
$0.00
#Azioni
10,182
Valore ($)
0
#Azioni Totale
50,348
Hansen GwennOct 30 '26
Chief Scientific Officer
Transazione
Option Exercise
Costo
$0.00
#Azioni
10,182
Valore ($)
0
#Azioni Totale
127,409

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
CHRISTINE RING	Officer	Nov 03 '26	Proposed Sale	$25.70	6,113	157,104	0
CHRISTINE RING	Officer	Nov 02 '26	Proposed Sale	$26.80	10,602	284,134	0
Hansen Gwenn	Chief Scientific Officer	Nov 02 '26	Sale	$26.80	1,452	38,914	123,452
Hansen Gwenn	Chief Scientific Officer	Nov 02 '26	Option Exercise	$1.86	1,452	2,701	124,904
Hansen Gwenn	Chief Scientific Officer	Oct 30 '26	Sale	$26.28	3,957	103,986	123,452
van Houte Hans	Chief Financial Officer	Oct 30 '26	Sale	$26.28	2,834	74,475	47,514
Ring Christine	Chief Legal Officer	Oct 30 '26	Option Exercise	$0.00	10,182	0	19,292
Ring Christine	Chief Legal Officer	Oct 30 '26	Sale	$26.28	3,957	103,986	15,335
van Houte Hans	Chief Financial Officer	Oct 30 '26	Option Exercise	$0.00	10,182	0	50,348
Hansen Gwenn	Chief Scientific Officer	Oct 30 '26	Option Exercise	$0.00	10,182	0	127,409

Nurix Therapeutics Inc Borsa (NRIX) Ultime notizie

Nov 02, 2026

Officer Christine Ring proposes selling 10,602 Nurix Therapeutics (NRIX) shares. - Stock Titan

Nov 02, 2026

Oct 30, 2026

Xencor, Inc. (XE9.F) Seasonal Returns Chart - Yahoo! Finance Canada

Oct 30, 2026

Oct 29, 2026

Nurix Therapeutics stock: Roche deal lifts Q3 revenue to USD 673.1m - ad-hoc-news.de

Oct 29, 2026

Oct 22, 2026

Roche's 9M 2026 Sales Rise on Strong Drug Demand, Pipeline Advances - Zacks Investment Research

Oct 22, 2026

Oct 19, 2026

Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth? - Zacks Investment Research

Oct 19, 2026

Mar 28, 2021

ABCL News | ABCELLERA BIOLOGICS INC (NASDAQ:ABCL) - ChartMill

Mar 28, 2021

Oct 15, 2026

Form 4 Nurix Therapeutics Inc: Gwenn Hansen (Chief Scientific Officer) For: 15 October By Investing.com - Investing.com South Africa

Oct 15, 2026

Nurix Therapeutics CSO Gwenn Hansen sells $36,300 in common stock - Investing.com

Oct 15, 2026

Nurix Therapeutics CSO Gwenn Hansen sells $36,300 in common stock By Investing.com - Investing.com Nigeria

Oct 15, 2026

Nurix director Gregory sells $528,528 in stock following option exercise By Investing.com - Investing.com UK

Oct 15, 2026

Nurix director Gregory sells $528,528 in stock following option exercise By Investing.com - Investing.com Nigeria

Oct 15, 2026

Form 4 Nurix Therapeutics Inc: Julia P. Gregory (Director) For: 14 October - Investing.com India

Oct 15, 2026

Nurix director Gregory sells $528,528 in stock following option exercise - Investing.com

Oct 15, 2026

Form 4 Nurix Therapeutics Inc: Julia P. Gregory (Director) For: 14 October - Investing.com Nigeria

Oct 15, 2026

Form 4 Nurix Therapeutics Inc: Julia P. Gregory (Director) For: 14 October - Investing.com Canada

Oct 15, 2026

Form 4 Nurix Therapeutics Inc: Julia P. Gregory (Director) For: 14 October - Investing.com UK

Oct 15, 2026

Nurix director Gregory sells $528,528 in stock following option exercise By Investing.com - Investing.com Canada

Oct 15, 2026

Oct 14, 2026

Nurix Therapeutics Director Sold Shares Worth Over $528K - TradingView

Oct 14, 2026

Nurix Therapeutics Insider Sold Shares Worth $528,528, According to a Recent SEC Filing - Yahoo Finance

Oct 14, 2026

A director proposes selling 22,583 Nurix Therapeutics (Nasdaq: NRIX) shares acquired by exercising options. - Stock Titan

Oct 14, 2026

A director exercises $1.86 options, then sells 22,583 Nurix Therapeutics (NRIX) shares. - Stock Titan

Oct 14, 2026

Oct 13, 2026

Form 4 Nurix Therapeutics Inc: Christine Ring (CLO) For: 2 October - Investing.com Australia

Oct 13, 2026

U.S. Analyst Updates: October 13th, 2026 - The Globe and Mail

Oct 13, 2026

Nurix Therapeutics CLO sells $134k in stock after option exercise - Investing.com

Oct 13, 2026

Form 4 Nurix Therapeutics Inc: Christine Ring (CLO) For: 2 October - Investing.com Canada

Oct 13, 2026

Form 4 Nurix Therapeutics Inc: Christine Ring (CLO) For: 2 October - Investing.com Nigeria

Oct 13, 2026

Form 4 Nurix Therapeutics Inc: Christine Ring (CLO) For: 2 October - Investing.com UK

Oct 13, 2026

Nurix Therapeutics CLO sells $134k in stock after option exercise - Investing.com UK

Oct 13, 2026

Oct 12, 2026

Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates - Zacks Investment Research

Oct 12, 2026

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance

Oct 12, 2026

Oct 07, 2026

The first patient has joined a trial testing two drugs for a type of blood cancer. - Stock Titan

Oct 07, 2026

Oct 05, 2026

Trade Figures, Fed in Picture This Week - baystreet.ca

Oct 05, 2026

Oct 02, 2026

An officer proposes selling 5,786 shares of Nurix Therapeutics (NRIX). - Stock Titan

Oct 02, 2026

Oct 01, 2026

Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock? - Zacks Investment Research

Oct 01, 2026

Sep 28, 2026

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock Has Consensus Price Target of $34.21 According to Analysts - MarketBeat

Sep 28, 2026

Sep 25, 2026

842,089 Shares in Nurix Therapeutics, Inc. $NRIX Bought by Bank of America Corp DE - MarketBeat

Sep 25, 2026

Sep 23, 2026

More than 5% of Nurix Therapeutics (NRIX) is reported by three parties, but one fund holds the shares. - Stock Titan

Sep 23, 2026

Sep 21, 2026

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates - Zacks Investment Research

Sep 21, 2026

Sep 18, 2026

Nurix Therapeutics, Inc. (NRIX) Stock Analysis: A Biotech Gem With A 33% Upside Potential - DirectorsTalk Interviews

Sep 18, 2026

AMC Global Media Inc. - Class A Common Stock (NQ: AMCX - The Chronicle-Journal

Sep 18, 2026

Sep 12, 2026

Behavioral Patterns of NRIX and Institutional Flows - Stock Traders Daily

Sep 12, 2026

Sep 11, 2026

We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth - Moomoo

Sep 11, 2026

Sep 10, 2026

Nurix Therapeutics, Inc. (NRIX) Latest Stock News & Headlines - Yahoo Finance

Sep 10, 2026

Here's Why You Should Add NRIX Stock to Your Portfolio Now - Yahoo Finance

Sep 10, 2026

Transcript : Nurix Therapeutics, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-08-2026 03 - marketscreener.com

Sep 10, 2026

Sep 09, 2026

Nurix Therapeutics (NRIX) Upgraded to Buy: Here's Why - Yahoo Finance

Sep 09, 2026

Sep 08, 2026

Nurix Therapeutics at Wells Fargo conference: pipeline, deal momentum By Investing.com - Investing.com India

Sep 08, 2026

Nurix Therapeutics at Wells Fargo conference: pipeline, deal momentum - investing.com

Sep 08, 2026

Sep 07, 2026

Legal & General Group Plc Buys Shares of 72,026 Nurix Therapeutics, Inc. $NRIX - MarketBeat

Sep 07, 2026

Sep 05, 2026

Nurix Therapeutics Stock Price Forecast. Should You Buy NRIX? - StockInvest.us

Sep 05, 2026

Simile a NRIX